Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • cRGDfV  (1)
  • immunohistochemistry  (1)
  • 1
    ISSN: 1573-7373
    Keywords: glioma ; tumor-associated antigen ; immunohistochemistry ; monoclonal antibody ; IgM
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The present study was undertaken to determine thepattern of immunoreactivity of BT32/A6, a human IgMmonoclonal antibody (MAb), with the following histological panels:1) 30 human and non-human cell lines, 2)32 normal human tissues, and 3) 28 tumorsof central neuroepithelial origin (16 astrocytic; 11 non-astro-cytic).Antibody BT32/A6 recognizes a surface and cytoplasmic antigenpresent on a variety of human tumor celllines including gliomas, melanomas, neuroblastomas, and a fewsarcomas. The antigen is present (at least focally)on 15/16 astrocytic tumor tissue sections (94%), andin some cases, on close to 100% ofcells. All malignant cell types, including small anaplasticcells, giant cells, gemistocytic cells, and cells formingpseudopalisades were labeled by MAb BT32/A6. Non-astrocytic neuroepithelialtumors did not stain appreciably with MAb BT32/A6.There was weak immunoreactivity in a small subsetof normal human tissues of epithelial and lymphoidorigin, with the exception of adrenal cortex, whichexhibited weak to moderate staining. All normal tissuesof neuroectodermal and mesenchymal origin were unreactive. Inconclusion, MAb BT32/A6 appears to be unique inthat it recognizes a highly-expressed astrocytic tumor-associated antigenthat is present on both low and highgrade tumors. This makes it a strong candidatefor further studies aimed at establishing its usefulnessin the treatment of human astrocytic tumors.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    Journal of neuro-oncology 46 (2000), S. 135-144 
    ISSN: 1573-7373
    Keywords: apoptosis ; cRGDfV ; human gliomas ; integrin αVβ3 ; mouse glioma model
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Glioblastoma multiforme (GBM) is the most frequent malignant brain tumor in adults and is invariably fatal. We have investigated the effect of cyclo-(Arg-Gly-Asp-D-Phe-Val) (cRGDfV) peptide on survival of human malignant glioma cells in vitro and in vivo. Immunofluorescent analyses revealed the presence of αVβ3 integrin on U-87MG and U-373MG cells, but minimal expression on U-251MG cells. Treatment of U-87MG and U-373MG cells in vitro with cRGDfV (20 µg/ml), but not the linear peptide, resulted in the appearance of rounded and loosely attached cells with subsequent cell death. By comparison, neither this cyclic peptide nor its linear homolog had any significant effect on growth and morphology of U-251MG cells. The death of cRGDfV-treated (20 µg/ml) glioma cells was blocked by pretreatment (10 µM) of cells with DEVD-FMK and LEHD-FMK, inhibitors of caspase-3 and caspase-9, respectively. Moreover, when glioma cells grown as spheroids were treated with cRGDfV (50 µg/ml), spheroid formation was markedly reduced. Further, treatment of intracranial U-87MG tumors in scid mice with cyclic peptide significantly (p〈0.001) prolonged their survival. These results indicated (i) that cRGDfV induced apoptosis of human glioma cells by binding αVβ3 integrin expressed on their cell surfaces and (ii) that cRGDfV may be an effective and non-toxic direct anti-tumor therapy for αVβ3-expressing GBMs.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...